Results 211 to 220 of about 628,481 (260)
Some of the next articles are maybe not open access.
Production of Single-Domain Antibodies in Pichia pastoris
2022Single-domain antibodies (sdAbs) are binders that consist of a single immunoglobulin domain. SdAbs have gained importance as therapeutics, diagnostic reagents, and research tools. Functional sdAbs are commonly produced in Escherichia coli, which is a simple and widely used host for production of recombinant proteins. However, there are drawbacks of the
Yusei, Matsuzaki +3 more
openaire +2 more sources
Expression of Single-Domain Antibodies in Bacterial Systems
2012In this chapter we describe in detail the current protocols that are used to express single-domain antibodies in bacteria. Bacteria are among the most common expression systems for expressing recombinant proteins. We present different approaches for carrying out periplasmic and cytoplasmic expression, as well as small-scale and large-scale expression ...
Baral, T.N., Arbabi-Ghahroudi, M.
openaire +3 more sources
Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies
International Reviews of Immunology, 2018Nanobodies for the first time were identified in the sera of Camelidae. Single-domain antibodies or nanobodies are a class of next-generation antibodies that have specific features: small size (in nanoscale), high penetration in various tissues, high stability in hard situations and ease production process in microbial systems.
Farnaz Khodabakhsh +3 more
openaire +2 more sources
Application of Single-Domain Antibodies in Tumor Histochemistry
2012High avidity, pentameric, single-domain antibodies, oligomerized through the B subunit of verotoxin, are excellent immunohistochemical reagents. The resulting molecules are termed pentabodies. Here, we describe the immunostaining of tissue sections with ES1, a pentabody recognizing CEACAM6 which is overexpressed in several cancers.
Maik, K.T., MacKenzie, C.R.
openaire +2 more sources
Single domain camel antibodies: current status
Reviews in Molecular Biotechnology, 2001The antigen-binding capacity of the paired variable domains of an antibody is well established. The observation that the isolated heavy chains of anti-hapten antibodies retain some antigen-binding capacity in the absence of light chains led to attempts to obtain an even smaller antigen-binding unit in a VH format.
openaire +3 more sources
Engineered antibody fragments and the rise of single domains
Nature Biotechnology, 2005With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals. In fact, by 2008, engineered antibodies are predicted to account for >30% of all revenues in the biotechnology market. Smaller recombinant antibody fragments (for example,
Philipp, Holliger, Peter J, Hudson
openaire +2 more sources
Improving the targeting of therapeutics with single-domain antibodies
Expert Opinion on Drug Delivery, 2016The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting
Kendrick B, Turner +3 more
openaire +2 more sources
Bispecific Single Domain Antibodies
2011Monoclonal antibodies are now widely recognized as therapeutic molecules and more than 25 molecules have been approved in the United States and other countries. Despite these successes, the clinical activity of these molecules is still far from optimal and new solutions have to be found, especially in the field of cancer therapy.
Patrick Chames, Daniel Baty
openaire +1 more source
Prospective Applications of Single-Domain Antibodies in Biomedicine
Molecular Biology, 2020Methods that utilize highly specific antibodies, anti-idiotypic antibodies, various recombinant molecules with antibody properties and immunocorrection and immunoprophylaxis with the help of vaccines are in demand and are intensely developed in the field of biomedicine.
openaire +2 more sources
2006
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source